Zealand Pharma (CPSE:ZEAL) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ZEAL Aperçu des actions

Zealand Pharma A/S, une société de biotechnologie, se consacre à la découverte, au développement et à la commercialisation de médicaments à base de peptides au Danemark.

A propos de l'entreprise

ZEAL analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	2/6
Performances passées	0/6
Santé financière	4/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 32.86% par an

Analyse des risques

Volatilité du cours de l'action au cours des 3 derniers mois

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Les actionnaires ont été dilués au cours de l'année écoulée

Zealand Pharma A/S Concurrents

Genmab

CPSE:GMAB

DKK 115.6b

Bavarian Nordic

CPSE:BAVA

DKK 22.1b

BioPorto

CPSE:BIOPOR

DKK 919.5m

H. Lundbeck

CPSE:HLUN B

DKK 42.2b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Zealand Pharma
Historique des cours de bourse
Prix actuel de l'action	DKK 874.00
Plus haut sur 52 semaines	DKK 972.00
Plus bas sur 52 semaines	DKK 252.60
Bêta	0.64
1Variation sur 1 mois	-0.68%
Variation sur 3 mois	44.94%
Variation sur 1 an	225.63%
3Variation sur 3 ans	397.72%
Variation sur 5 ans	575.43%
Évolution depuis l'introduction en bourse	999.37%

Nouvelles et mises à jour récentes

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Aug 21

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 18

Recent updates

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Aug 21

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 18

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Mar 17

Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation

Oct 03

Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term

Aug 14

Some Zealand Pharma A/S (CPH:ZEAL) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 14

Is Zealand Pharma's (CPH:ZEAL) 113% Share Price Increase Well Justified?

Mar 11

What You Need To Know About Zealand Pharma A/S' (CPH:ZEAL) Investor Composition

Jan 12

Rendement pour les actionnaires

	ZEAL	DK Biotechs	DK Marché
7D	-3.9%	2.5%	-0.3%
1Y	225.6%	3.9%	25.4%

Rendement vs Industrie: ZEAL a dépassé le secteur Danish Biotechs qui a rapporté 8.2 % au cours de l'année écoulée.

Rendement vs marché: ZEAL a dépassé le marché Danish qui a rapporté 27.3 % au cours de l'année écoulée.

Volatilité des prix

Is ZEAL's price volatile compared to industry and market?
ZEAL volatility
ZEAL Average Weekly Movement	8.9%
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.3%
10% most volatile stocks in DK Market	9.1%
10% least volatile stocks in DK Market	2.8%

Cours de l'action stable: Le cours de l'action de ZEAL a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de ZEAL ( 9% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de Danish.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1997	288	Adam Steensberg	www.zealandpharma.com

Zealand Pharma A/S, une société de biotechnologie, se consacre à la découverte, au développement et à la commercialisation de médicaments à base de peptides au Danemark. Elle dispose d'un portefeuille de médicaments axés sur les maladies gastro-intestinales et métaboliques, ainsi que sur d'autres maladies spécialisées dont les besoins médicaux ne sont pas satisfaits. La société propose le Dasiglucagon, une seringue à usage unique ou un auto-injecteur pour le traitement de l'hypoglycémie sévère, et les systèmes de pancréas artificiels bi-hormonaux Dasiglucagon contenant de l'insuline et du Dasiglucagon.

Zealand Pharma A/S Résumé des fondamentaux

Comment les bénéfices et les revenus de Zealand Pharma se comparent-ils à sa capitalisation boursière ?
ZEAL statistiques fondamentales
Capitalisation boursière	DKK 63.19b
Bénéfices(TTM)	-DKK 712.00m
Recettes(TTM)	DKK 367.97m

168.5x

Ratio P/S

-87.1x

Ratio P/E

Le site ZEAL est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ZEAL compte de résultat (TTM)
Recettes	DKK 367.97m
Coût des recettes	DKK 714.45m
Marge brute	-DKK 346.47m
Autres dépenses	DKK 365.53m
Les revenus	-DKK 712.00m

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

Nov 07, 2024

Résultat par action (EPS)	-10.04
Marge brute	-94.16%
Marge bénéficiaire nette	-193.49%
Ratio dettes/capitaux propres	2.9%

Quelles ont été les performances à long terme de ZEAL?

Voir les performances historiques et les comparaisons

ZEAL Aperçu des actions

Récompenses

Analyse des risques

Zealand Pharma A/S Concurrents

CPSE:GMAB

DKK 115.6b

CPSE:BAVA

DKK 22.1b

CPSE:BIOPOR

DKK 919.5m

CPSE:HLUN B

DKK 42.2b

Historique des prix et performances

Nouvelles et mises à jour récentes

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 40%

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Recent updates

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 40%

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Consensus forecasts updated

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to kr.229

Zealand Pharma Announces CEO Changes

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Full year 2021 earnings: Revenues in line with analyst expectations

Consensus forecasts updated

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Consensus forecasts updated

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Price target decreased to kr.228

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Price target decreased to kr.236

Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term

Consensus EPS estimates fall to -kr.28.75

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection